Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT)

Winichakoon, Poramed; Wipasa, Jiraprapa; Chawansuntati, Kriangkrai; Salee, Parichat; Sudjaritruk, Tavitiya; Yasri, Saowaluck; Khamwan, Chantana; Peerakam, Rungnapa; Dankai, Dararat; Chaiwarith, Romanee

doi:10.1038/s41598-022-26202-1

Cited by 9 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, neutralization assays can be especially costly and labour-intensive. 68,69 Several factors preceding (e.g. age, sex and comorbidities) 3,4,15,[18][19][20] and during (hyperinflammation, immunodepression and varying immunomodulatory strategies) 21,[23][24][25][26][27][28][29][30] SARS-CoV-2 infection may influence long COVID manifestations and post-infection serological trends.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Serological markers and long COVID—A rapid systematic review

Collins,

Philippe,

Gravel

et al. 2023

Eur J Clin Investigation

View full text Add to dashboard Cite

BackgroundLong COVID is highly heterogeneous, often debilitating, and may last for years after infection. The aetiology of long COVID remains uncertain. Examination of potential serological markers of long COVID, accounting for clinical covariates, may yield emergent pathophysiological insights.MethodsIn adherence to PRISMA guidelines, we carried out a rapid review of the literature. We searched Medline and Embase for primary observational studies that compared IgG response in individuals who experienced COVID‐19 symptoms persisting ≥12 weeks post‐infection with those who did not. We examined relationships between serological markers and long COVID status and investigated sources of inter‐study variability, such as severity of acute illness, long COVID symptoms assessed and target antigen(s).ResultsOf 8018 unique records, we identified 29 as being eligible for inclusion in synthesis. Definitions of long COVID varied. In studies that reported anti‐nucleocapsid (N) IgG (n = 10 studies; n = 989 participants in aggregate), full or partial anti‐Spike IgG (i.e. the whole trimer, S1 or S2 subgroups, or receptor binding domain, n = 19 studies; n = 2606 participants), or neutralizing response (n = 7 studies; n = 1123 participants), we did not find strong evidence to support any difference in serological markers between groups with and without persisting symptoms. However, most studies did not account for severity or level of care required during acute illness, and other potential confounders.ConclusionsPooling of studies would enable more robust exploration of clinical and serological predictors among diverse populations. However, substantial inter‐study variations hamper comparability. Standardized reporting practices would improve the quality, consistency and comprehension of study findings.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Such endeavours demand extensive commitments of time and effort from multidisciplinary research groups, and necessitate substantial funds for study design, implementation and maintenance. Notably, neutralization assays can be especially costly and labour‐intensive 68,69 …”

Section: Discussionmentioning

confidence: 99%

Serological markers and long COVID—A rapid systematic review

Collins,

Philippe,

Gravel

et al. 2023

Eur J Clin Investigation

View full text Add to dashboard Cite

show abstract

“…Such endeavours demand extensive commitments of time and effort from multidisciplinary research groups, and necessitate substantial funds for study design, implementation, and maintenance. Notably, neutralization assays can be especially costly and labour-intensive [71,72].…”

Section: Discussionmentioning

confidence: 99%

Serological markers and Post COVID-19 Condition (PCC) – A rapid review of the evidence

Collins,

Philippe,

Gravel

et al. 2023

Preprint

View full text Add to dashboard Cite

BackgroundPost COVID-19 Condition (PCC) is highly heterogeneous, often debilitating, and may last for years after infection. The etiology of PCC remains uncertain. Examination of potential serological markers of PCC, accounting for clinical covariates, may yield emergent pathophysiological insights.MethodsIn adherence to PRISMA guidelines, we carried out a rapid review of the literature. We searched Medline and Embase for primary observational studies that compared IgG response in individuals who experienced COVID-19 symptoms persisting ≥12 weeks post-infection with those who did not. We examined relationships between serological markers and PCC status and investigated sources of inter-study variability, such as severity of acute illness, PCC symptoms assessed, and target antigen(s).ResultsOf 8,018 unique records, we identified 29 as being eligible for inclusion in synthesis. Definitions of PCC varied. In studies that reported anti-nucleocapsid (N) IgG (n=10 studies; n=989 participants in aggregate), full or partial anti-Spike IgG (i.e., the whole trimer, S1 or S2 subgroups, or receptor binding domain, n=19 studies; n=2606 participants), or neutralizing response (n=7 studies; n=1123 participants), we did not find strong evidence to support any difference in serological markers between groups with and without persisting symptoms. However, most studies did not account for severity or level of care required during acute illness, and other potential confounders.ConclusionsPooling of studies would enable more robust exploration of clinical and serological predictors among diverse populations. However, substantial inter-study variations hamper comparability. Standardized reporting practices would improve the quality, consistency, and comprehension of study findings.

show abstract

“…Anti-SARS-CoV-2 spike protein immunoglobulin G (IgG) were determined by indirect enzyme-linked immunosorbent assay (ELISA) as described previously [10] . In brief, MaxiSorp™ ELISA plates (Thermo Fisher Scientific, Roskilde, Denmark) were coated with recombinant spike protein (GenScript, Piscataway, USA) in bicarbonate buffer (pH 9.6) and stored overnight at 4 °C.…”

Section: Methodsmentioning

confidence: 99%

Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand

Chawansuntati,

Sakkhachornphop,

Hongjaisee

et al. 2024

Vaccine: X

Self Cite

View full text Add to dashboard Cite

Diagnostic performance between in-house and commercial SARS-CoV-2 serological immunoassays including binding-specific antibody and surrogate virus neutralization test (sVNT)

Cited by 9 publications

References 38 publications

Serological markers and long COVID—A rapid systematic review

Serological markers and long COVID—A rapid systematic review

Serological markers and Post COVID-19 Condition (PCC) – A rapid review of the evidence

Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand

Contact Info

Product

Resources

About